Literature DB >> 16343379

Measuring adherence to highly active antiretroviral therapy: implications for research and practice.

Thomas Kerr1, John Walsh, Elisa Lloyd-Smith, Evan Wood.   

Abstract

Highly active antiretroviral therapy (HAART) has radically changed the course of HIV disease, producing substantial reductions in both HIV-related morbidity and mortality. However, the complexity of the typical daily HAART regimen is substantial, and high levels of adherence are essential for complete and long-term viral suppression and the avoidance of drug resistance. The complexity of HAART has made the assessment of medication adherence of paramount importance. Even though various methods are in use, each measures only a subset of adherence behaviors, and each measure has limited predictive validity. Given the individual and public health concerns associated with adherence to HAART, there is a need for the continued development and validation of measures of medication adherence.

Entities:  

Mesh:

Year:  2005        PMID: 16343379     DOI: 10.1007/s11904-005-0017-3

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  47 in total

1.  Measuring medication adherence: is assessment of missed doses sufficient?

Authors:  G J Wagner; J G Rabkin
Journal:  AIDS       Date:  1999-12-03       Impact factor: 4.177

Review 2.  Measuring adherence to antiretroviral medications in clinical trials.

Authors:  L G Miller; R D Hays
Journal:  HIV Clin Trials       Date:  2000 Jul-Aug

Review 3.  Misattribution, false recognition and the sins of memory.

Authors:  D L Schacter; C S Dodson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-09-29       Impact factor: 6.237

4.  Computer-assisted self-interviewing (CASI) to improve provider assessment of adherence in routine clinical practice.

Authors:  David R Bangsberg; Amy Bronstone; Margaret A Chesney; Federick M Hecht
Journal:  J Acquir Immune Defic Syndr       Date:  2002-12-15       Impact factor: 3.731

5.  Memory for memory.

Authors:  S Joslyn; E Loftus; A McNoughton; J Powers
Journal:  Mem Cognit       Date:  2001-09

6.  Barriers to HAART adherence among human immunodeficiency virus-infected adolescents.

Authors:  Debra A Murphy; Moussa Sarr; Stephen J Durako; Anna-Barbara Moscicki; Craig M Wilson; Larry R Muenz
Journal:  Arch Pediatr Adolesc Med       Date:  2003-03

7.  Provider assessment of adherence to HIV antiretroviral therapy.

Authors:  D R Bangsberg; F M Hecht; H Clague; E D Charlebois; D Ciccarone; M Chesney; A Moss
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-15       Impact factor: 3.731

8.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

9.  Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.

Authors:  Thomas Kerr; Anita Palepu; Gordon Barness; John Walsh; Robert Hogg; Julio Montaner; Mark Tyndall; Evan Wood
Journal:  Antivir Ther       Date:  2004-06

10.  Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.

Authors:  Evan Wood; Robert S Hogg; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

View more
  14 in total

Review 1.  Practical and conceptual challenges in measuring antiretroviral adherence.

Authors:  Karina M Berg; Julia H Arnsten
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

Review 2.  Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011.

Authors:  Cathy M Puskas; Jamie I Forrest; Surita Parashar; Kate A Salters; Angela M Cescon; Angela Kaida; Cari L Miller; David R Bangsberg; Robert S Hogg
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

3.  Reliability and validity of daily self-monitoring by smartphone application for health-related quality-of-life, antiretroviral adherence, substance use, and sexual behaviors among people living with HIV.

Authors:  Dallas Swendeman; W Scott Comulada; Nithya Ramanathan; Maya Lazar; Deborah Estrin
Journal:  AIDS Behav       Date:  2015-02

4.  Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.

Authors:  Jessica E Haberer; Nicholas Musinguzi; Yap Boum; Mark J Siedner; A Rain Mocello; Peter W Hunt; Jeffrey N Martin; David R Bangsberg
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-01       Impact factor: 3.731

5.  Association between living with children and adherence to highly active antiretroviral therapy in the Women's Interagency HIV Study.

Authors:  Daniel J Merenstein; Michael F Schneider; Christopher Cox; Rebecca Schwartz; Kathleen Weber; Esther Robison; Monica Gandhi; Jean Richardson; Michael W Plankey
Journal:  Pediatrics       Date:  2008-04       Impact factor: 7.124

6.  Real-time adherence monitoring for HIV antiretroviral therapy.

Authors:  Jessica E Haberer; Josh Kahane; Isaac Kigozi; Nneka Emenyonu; Peter Hunt; Jeffrey Martin; David R Bangsberg
Journal:  AIDS Behav       Date:  2010-12

7.  High-intensity cannabis use and adherence to antiretroviral therapy among people who use illicit drugs in a Canadian setting.

Authors:  Gregory Slawson; M-J Milloy; Lynda Balneaves; Annick Simo; Silvia Guillemi; Robert Hogg; Julio Montaner; Evan Wood; Thomas Kerr
Journal:  AIDS Behav       Date:  2015-01

8.  Correlation between pill counts and biologic effects in an HIV-1 prevention clinical trial: implications for measuring adherence.

Authors:  Deborah J Donnell; Jared M Baeten; Ting Hong; Jairam R Lingappa; Andrew Mujugira; Edith Nakku-Joloba; David Bangsberg; Connie Celum
Journal:  AIDS Behav       Date:  2013-02

9.  Assessing medication adherence: options to consider.

Authors:  Audrey Lehmann; Parisa Aslani; Rana Ahmed; Jennifer Celio; Aurelie Gauchet; Pierrick Bedouch; Olivier Bugnon; Benoît Allenet; Marie Paule Schneider
Journal:  Int J Clin Pharm       Date:  2013-10-29

10.  Realtime adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda.

Authors:  Jessica E Haberer; Julius Kiwanuka; Denis Nansera; Conrad Muzoora; Peter W Hunt; Jacquelyn So; Michael O'Donnell; Mark Siedner; Jeffrey N Martin; David R Bangsberg
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.